The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Hot melt extrusion (HME) technology, originally adapted from the food and plastics industries, has become increasingly valuable in the healthcare sector due to its effectiveness in developing novel pharmaceutical formulations. HME is a continuous manufacturing process in which active ingredients, polymers, and processing aids are fed into the extruder and subjected to high shear and temperatures, forming a homogeneous matrix with the desired characteristics.
The rapid growth of hot melt extrusion technology in the pharmaceutical industry is driven by its ability to overcome many challenges associated with traditional drug manufacturing methods. With a thorough understanding of the process, HME can be utilized to modify properties that enhance solubility, prevent abuse, and adjust the release profile, ultimately leading to the development of high-quality pharmaceutical formulations that are both safe and effective for patients.
Our new white paper dives into HME and its pharmaceutical applications and explores the capabilities of Thermo Fisher Scientific as a CDMO partner for drug development.
